Abstract：
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a prevalent and preventable condition. Mesenchymal stem cell (MSC) therapy is being explored to aid in the regeneration of lung cells and airway structure, aiming to restore lung function.
OBJECTIVE: To examine varied responses of MSCs when cultured with peripheral blood mononuclear cells (PBMCs) from different COPD phenotypes, patients were grouped into ACOS, emphysema, and chronic bronchitis categories.
METHODS: PBMCs from these groups and controls were co-cultured with MSCs derived from dental follicles, revealing differing rates of apoptosis among COPD phenotypes compared to controls.
RESULTS: While the chronic bronchitis group exhibited the least lymphocyte viability (p<0.01), introducing MSCs notably enhanced viability across all phenotypes except emphysema, with the chronic bronchitis group showing the most improvement (p<0.05).
CONCLUSIONS: Stem cell therapy might reduce peripheral lymphocyte apoptosis in COPD, with varying responses based on phenotype, necessitating further research to understand mechanisms and optimize tailored therapies for each COPD subtype.
OBJECTIVE: To examine varied responses of MSCs when cultured with peripheral blood mononuclear cells (PBMCs) from different COPD phenotypes, patients were grouped into ACOS, emphysema, and chronic bronchitis categories.
METHODS: PBMCs from these groups and controls were co-cultured with MSCs derived from dental follicles, revealing differing rates of apoptosis among COPD phenotypes compared to controls.
RESULTS: While the chronic bronchitis group exhibited the least lymphocyte viability (p<0.01), introducing MSCs notably enhanced viability across all phenotypes except emphysema, with the chronic bronchitis group showing the most improvement (p<0.05).
CONCLUSIONS: Stem cell therapy might reduce peripheral lymphocyte apoptosis in COPD, with varying responses based on phenotype, necessitating further research to understand mechanisms and optimize tailored therapies for each COPD subtype.
摘要：
背景：慢性阻塞性肺疾病（COPD）是一种普遍且可预防的疾病。正在探索间充质干细胞（MSC）疗法，以帮助肺细胞和气道结构的再生，旨在恢复肺功能。
目的：为了检查MSCs与来自不同COPD表型的外周血单核细胞（PBMC）培养时的不同反应，患者被分组为ACOS，肺气肿,和慢性支气管炎类别。
方法：将这些组和对照组的PBMC与牙囊来源的MSCs共培养，揭示了与对照组相比，COPD表型的细胞凋亡率不同。
结果：慢性支气管炎组淋巴细胞活力最低（p<0.01），在除肺气肿外的所有表型中引入MSCs，慢性支气管炎组改善最明显(p<0.05)。
结论：干细胞治疗可减少COPD患者外周血淋巴细胞凋亡，根据表型不同的反应，需要进一步研究以了解机制并优化针对每种COPD亚型的定制疗法。
目的：为了检查MSCs与来自不同COPD表型的外周血单核细胞（PBMC）培养时的不同反应，患者被分组为ACOS，肺气肿,和慢性支气管炎类别。
方法：将这些组和对照组的PBMC与牙囊来源的MSCs共培养，揭示了与对照组相比，COPD表型的细胞凋亡率不同。
结果：慢性支气管炎组淋巴细胞活力最低（p<0.01），在除肺气肿外的所有表型中引入MSCs，慢性支气管炎组改善最明显(p<0.05)。
结论：干细胞治疗可减少COPD患者外周血淋巴细胞凋亡，根据表型不同的反应，需要进一步研究以了解机制并优化针对每种COPD亚型的定制疗法。
